Navigation Links
Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
Date:2/12/2008

WOBURN, Mass., Feb. 12 /PRNewswire/ -- AdvanDx announced it has named Else Beth Trautner, a former Executive Vice President of Dako A/S, as Vice President of Sales and Marketing. Ms. Trautner will aggressively drive the global adoption of AdvanDx's fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. Ms. Trautner previously managed an organization of more than 575 employees with annual revenues in excess of $300 million at Dako, a global cancer diagnostics company, while successfully restructuring business operations in the Asia-Pacific region that led to record sales. Ms. Trautner also orchestrated the reorganization of 22 sales subsidiaries into 5 geographic regions resulting in 15% sales growth and a 9% increase in profitability during her tenure as Executive Vice President of Global Sales at Dako.

"Ms. Trautner is a seasoned executive with proven industry experience who will drive aggressive growth, market expansion, revenue production and ultimately profitability," said Thais T. Johansen, President and CEO of AdvanDx. "The addition of Ms. Trautner clearly positions AdvanDx to deliver our easy-to-use, life saving molecular diagnostic products worldwide to help treat patients afflicted with serious infections," Mr. Johansen added.

"I am pleased to join AdvanDx's strong business and scientific management team as we make significant inroads into multi-billion dollar markets," said Else Beth Trautner, Vice President of Sales and Marketing at AdvanDx. "I look forward to ramping our success in North America while opening up new markets, seizing revenue-generating sales opportunities and further accelerating the adoption of our products in the global marketplace," said Ms. Trautner.

About AdvanDx

AdvanDx is the world's leading provider of fast, accurate and easy-to-use in vitro molecular diagnostic products that advance the prevention, diagnosis and treatment of infectious pathogens. AdvanDx's products and services enable dramatic improvements in patient care and outcomes while reducing hospital costs.

Every year, 350,000 patients contract bloodstream infections, causing over 90,000 unnecessary deaths and significant costs to the healthcare system. The rapid identification of infecting pathogens is crucial to ensure early and appropriate therapy to save lives and reduce patient length-of-stay. In response, AdvanDx leverages its molecular diagnostic products to detect and identify infectious pathogens and provide therapy-directing results in hours versus days.

AdvanDx's easy-to-use products employ standard lab techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products, supported by a global network of service partners.

For more information visit http://www.AdvanDx.com


'/>"/>
SOURCE AdvanDx
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Acrongenomics on Track to Acquire Molecular Vision
2. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
3. Acrongenomics Acquires Equity Stake in Molecular Vision
4. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
5. The Dark Report and Siemens Introduce the Worlds First Integrated Molecular Summit
6. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
7. Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):